Core Viewpoint - AnuoYuda Gene Technology (Beijing) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CCB International and Guotai Junan International as joint sponsors. The company previously submitted its listing application on March 25 [1]. Company Overview - AnuoYuda specializes in molecular diagnostics-based IVD medical devices and multi-omics life science research services, particularly focusing on NGS-based prenatal testing IVD products. Its clinical sequencing solutions include self-produced IVD testing kits, gene sequencers, and bioinformatics analysis software, along with technical support and laboratory design services [3][4]. - The company's clients primarily consist of hospitals certified for prenatal diagnosis and independent medical laboratories (ICLs), which purchase IVD products and pay fees based on the quantity and type of products purchased [3]. Market Position - AnuoYuda's NIPT testing kit, aimed at detecting the three most common chromosomal disorders (trisomy 21, 18, and 13), received a Class III medical device certificate in 2017, establishing its market position in prenatal testing. According to ZhiShi Consulting, the company ranks second in the Chinese NIPT market by sample testing volume in 2024, with market shares of 11.6%, 12.1%, and 15.5% for 2022, 2023, and 2024, respectively. By revenue, the company ranks third in the Chinese NIPT market with a market share of 14.6% [3]. Business Segments - The clinical sequencing solutions business line involves sourcing reagents and equipment components from upstream suppliers, then selling IVD testing kits, proprietary gene sequencers, and bioinformatics software directly or through distributors to hospitals and independent medical laboratories. The company focuses on two IVD testing kits approved by the National Medical Products Administration, specifically for reproductive health sequencing [4]. - In the research sequencing solutions business line, the company procures gene sequencers, testing kits, and other equipment from upstream suppliers to provide six types of research sequencing solutions for academic institutions, research organizations, and corporate clients, primarily in agriculture, forestry, animal husbandry, and fisheries [4]. Production Capacity - As of September 23, 2025, AnuoYuda operates three production facilities in China, primarily manufacturing testing kits and sequencers. The combined annual production capacity during the reporting period is 40 units of NextSeq 550AR sequencers and 48,000 testing kits [4]. Financial Performance - The company reported continuous operating revenue of approximately RMB 435.145 million, RMB 474.754 million, RMB 518.088 million, and RMB 268.667 million for the six months ending June 30 in 2022, 2023, 2024, and 2025, respectively. The annual losses were approximately RMB 66.812 million, RMB 240.242 million, RMB 125.761 million, and RMB 29.006 million for the same periods [5][6].
新股消息 | 安诺优达再度递表港交所 报告期内累计亏损超4.6亿元
Zhi Tong Cai Jing·2025-10-01 02:16